A Phase 4 interventional study of Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR) and Placebo in Attention-Deficit/Hyperactivity Disorder (ADHD), sponsored by Novartis Pharmaceuticals. Completed at 8 sites in United States. Open to participants aged 6 Years to 12 Years. Per ClinicalTrials.gov, last updated 2011-06-08.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Attention Deficit Disorder with Hyperactivity by Novartis — none open to participants now, none under way, none of them phase 3. Attention Deficit Disorder with Hyperactivity · Novartis.
Among the 10 studies in Attention Deficit Disorder with Hyperactivity by Novartis, this one is the 4th largest by enrollment, is the only one that started in 2008, is one of 2 in phase 4, and was the 8th registered.
1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.
Browse Attention Deficit Disorder with Hyperactivity studies →None of the 10 studies in Attention Deficit Disorder with Hyperactivity by Novartis is open now. The open studies under Attention Deficit Disorder with Hyperactivity, anywhere →
Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.
This study: 6 Years to 12 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 165 is above the median of 71 across 1,437 interventional studies indexed under Attention Deficit Disorder with Hyperactivity.
Median enrollment 146 across the 10 interventional studies. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Attention Deficit Disorder with Hyperactivity by Novartis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and safety of Dex-Methylphenidate Extended Release 30 mg compared to 20 mg in pediatric patients ages 6-12 with Attention-Deficit Hyperactivity Disorder (ADHD) in a 12-hour laboratory classroom setting.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dex-Methylphenidate hydrochloride (Focalin® XR) 30 mg dose (one 20 mg capsule and one 10 mg capsule) orally once a day for 7 days.
Drug: Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR)
Dex-Methylphenidate hydrochloride (Focalin® XR) one 20 mg capsule orally once a day for 7 days.
Drug: Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR)
Two Capsules taken orally once a day for 7 days
Drug: Placebo
10 mg and/or 20 mg capsules
Placebo Comparator
Change From Pre-dose in the Swanson, Kotkin, Agler, M Flynn, and Pelham (SKAMP) Combined Attention and Deportment Scores at 10, 11, and 12 Hour (Averaged) Post-dose
SKAMP is a 13-item rating scale that measures classroom manifestations of ADHD consisting of 2 subscales (7 items for Attention and 6 items for Deportment) used to generate a score at Hours 10, 11 and 12 on Day 7 of Weeks 1, 2 and 3. The ratings were based on both frequency and quality of specific behaviors. The rating scale is 0 (normal, no impairment) to 6 (maximum impairment) for a total possible combined score of 0 to 78. The reported measure is the difference from baseline of the 2 combined subscores averaged over Hours 10, 11 and 12. A negative score indicates improvement.
Time frame: Pre-dose to 10, 11, and 12 hours post-dose
Change From Pre-dose in the Swanson, Kotkin, Agler, M Flynn, and Pelham (SKAMP) Attention Score at 10, 11, and 12 Hour (Averaged) Post-dose
SKAMP is a 13-item rating scale consisting of 2 subscales (7-items for Attention and 6-items for Deportment) that measures classroom manifestations of ADHD. SKAMP was used to generate a score on the Attention subscale at Hours 10, 11, and 12 on Day 7 of Weeks 1, 2, and 3. The rating scale is 0 (normal, no impairment) to 6 (maximum impairment) for a total possible combined score of 0 to 42 for the Attention subscale. The reported measure is the difference from baseline of the subscore averaged over Hours 10, 11, and 12. A negative score indicates improvement.
Time frame: Pre-dose to 10, 11, and 12 hours post-dose
Change From Pre-dose in the Swanson, Kotkin, Agler, M Flynn, and Pelham (SKAMP) Deportment Score at 10, 11, and 12 Hour (Averaged) Post-dose
SKAMP is a 13-item rating scale consisting of 2 subscales (7-items for Attention and 6-items for Deportment) that measures classroom manifestations of ADHD. SKAMP was used to generate a score on the Deportment subscale at Hours 10, 11, and 12 on Day 7 of Weeks 1, 2, and 3. The rating scale is 0 (normal, no impairment) to 6 (maximum impairment) for a total possible combined score of 0 to 36 for the Deportment subscale. The reported measure is the difference from baseline of the subscore averaged over Hours 10, 11, and 12. A negative score indicates improvement.
Time frame: Pre-dose to 10, 11, and 12 hours post-dose
Change From Pre-dose in the Permanent Product Measure of Performance of Measurement (PERMP) Math Test-Attempted Score at 10, 11, and 12 Hours (Averaged) Post-dose
Permanent Product Measure of Performance of Measurement (PERMP) is an age-adjusted, paper-and-pencil math test consisting of 5 pages of 80 math problems each presented in ascending order of difficulty (requiring addition, subtraction, multiplication, and division computations, respectively) during a 10-minute time period. At the end of the 10-minute math test, papers are collected and scored; the number of problems attempted and the number of problems correctly answered are generated as objective measures related to "academic productivity." A positive score indicates improvement.
Time frame: Pre-dose to 10, 11, and 12 hours post-dose
Change From Pre-dose in the Permanent Product Measure of Performance of Measurement (PERMP) Math Test-Correctly Answered Score at 10, 11, and 12 Hours (Averaged) Post-dose
Permanent Product Measure of Performance of Measurement (PERMP) is an age-adjusted, paper-and-pencil math test consisting of 5 pages of 80 math problems each presented in ascending order of difficulty (requiring addition, subtraction, multiplication, and division computations, respectively) during a 10-minute time period. At the end of the 10-minute math test, papers are collected and scored; the number of problems attempted and the number of problems correctly answered are generated as objective measures related to "academic productivity." A positive score indicates improvement.
Time frame: Pre-dose to 10, 11, and 12 hours post-dose
| Milestone | Focalin XR 20 mg First, Then Focalin XR 30 mg, Then Placebo | Focalin XR 30 mg First, Then Placebo, Then Focalin XR 20 mg | Focalin XR 30 mg First, Then Focalin XR 20 mg, Then Placebo | Placebo First, Then Focalin XR 20 mg, Then Focalin XR 30 mg | Focalin XR 20 mg First, Then Placebo, Then Focalin XR 30 mg | Placebo First, Then Focalin XR 30 mg, Then Focalin XR 20 mg |
|---|---|---|---|---|---|---|
| Started | 26 | 28 | 29 | 27 | 28 | 27 |
| Completed | 26 | 27 | 28 | 27 | 26 | 27 |
| Not completed | 0 | 1 | 1 | 0 | 2 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 | 1 | 0 |
| Milestone | Focalin XR 20 mg First, Then Focalin XR 30 mg, Then Placebo | Focalin XR 30 mg First, Then Placebo, Then Focalin XR 20 mg | Focalin XR 30 mg First, Then Focalin XR 20 mg, Then Placebo | Placebo First, Then Focalin XR 20 mg, Then Focalin XR 30 mg | Focalin XR 20 mg First, Then Placebo, Then Focalin XR 30 mg | Placebo First, Then Focalin XR 30 mg, Then Focalin XR 20 mg |
|---|---|---|---|---|---|---|
| Started | 26 | 27 | 28 | 27 | 26 | 27 |
| Completed | 25 | 27 | 27 | 27 | 26 | 26 |
| Not completed | 1 | 0 | 1 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Protocol violation | 1 | 0 | 1 | 0 | 0 | 0 |
| Milestone | Focalin XR 20 mg First, Then Focalin XR 30 mg, Then Placebo | Focalin XR 30 mg First, Then Placebo, Then Focalin XR 20 mg | Focalin XR 30 mg First, Then Focalin XR 20 mg, Then Placebo | Placebo First, Then Focalin XR 20 mg, Then Focalin XR 30 mg | Focalin XR 20 mg First, Then Placebo, Then Focalin XR 30 mg | Placebo First, Then Focalin XR 30 mg, Then Focalin XR 20 mg |
|---|---|---|---|---|---|---|
| Started | 25 | 27 | 27 | 27 | 26 | 26 |
| Completed | 24 | 27 | 27 | 27 | 26 | 26 |
| Not completed | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 | 0 | 0 |
SKAMP is a 13-item rating scale that measures classroom manifestations of ADHD consisting of 2 subscales (7 items for Attention and 6 items for Deportment) used to generate a score at Hours 10, 11 and 12 on Day 7 of Weeks 1, 2 and 3. The ratings were based on both frequency and quality of specific behaviors. The rating scale is 0 (normal, no impairment) to 6 (maximum impairment) for a total possible combined score of 0 to 78. The reported measure is the difference from baseline of the 2 combined subscores averaged over Hours 10, 11 and 12. A negative score indicates improvement.
| Scores on a scale | Dex-Methylphenidate Hydrochloride (Focalin XR) 20 mg | Dex-Methylphenidate Hydrochloride (Focalin XR) 30 mg | Placebo |
|---|---|---|---|
| Change From Pre-dose in the Swanson, Kotkin, Agler, M Flynn, and Pelham (SKAMP) Combined Attention and Deportment Scores at 10, 11, and 12 Hour (Averaged) Post-dose | -2.02 ± 0.717 | -4.47 ± 0.724 | 4.50 ± .723 |
SKAMP is a 13-item rating scale consisting of 2 subscales (7-items for Attention and 6-items for Deportment) that measures classroom manifestations of ADHD. SKAMP was used to generate a score on the Attention subscale at Hours 10, 11, and 12 on Day 7 of Weeks 1, 2, and 3. The rating scale is 0 (normal, no impairment) to 6 (maximum impairment) for a total possible combined score of 0 to 42 for the Attention subscale. The reported measure is the difference from baseline of the subscore averaged over Hours 10, 11, and 12. A negative score indicates improvement.
| Scores on a scale | Dex-Methylphenidate Hydrochloride (Focalin XR) 20 mg | Dex-Methylphenidate Hydrochloride (Focalin XR) 30 mg | Placebo |
|---|---|---|---|
| Change From Pre-dose in the Swanson, Kotkin, Agler, M Flynn, and Pelham (SKAMP) Attention Score at 10, 11, and 12 Hour (Averaged) Post-dose | -1.33 ± 0.397 | -2.62 ± 0.400 | 0.94 ± 0.405 |
SKAMP is a 13-item rating scale consisting of 2 subscales (7-items for Attention and 6-items for Deportment) that measures classroom manifestations of ADHD. SKAMP was used to generate a score on the Deportment subscale at Hours 10, 11, and 12 on Day 7 of Weeks 1, 2, and 3. The rating scale is 0 (normal, no impairment) to 6 (maximum impairment) for a total possible combined score of 0 to 36 for the Deportment subscale. The reported measure is the difference from baseline of the subscore averaged over Hours 10, 11, and 12. A negative score indicates improvement.
| Scores on a scale | Dex-Methylphenidate Hydrochloride (Focalin XR) 20 mg | Dex-Methylphenidate Hydrochloride (Focalin XR) 30 mg | Placebo |
|---|---|---|---|
| Change From Pre-dose in the Swanson, Kotkin, Agler, M Flynn, and Pelham (SKAMP) Deportment Score at 10, 11, and 12 Hour (Averaged) Post-dose | -0.39 ± 0.423 | -1.49 ± 0.426 | 2.95 ± 0.424 |
Permanent Product Measure of Performance of Measurement (PERMP) is an age-adjusted, paper-and-pencil math test consisting of 5 pages of 80 math problems each presented in ascending order of difficulty (requiring addition, subtraction, multiplication, and division computations, respectively) during a 10-minute time period. At the end of the 10-minute math test, papers are collected and scored; the number of problems attempted and the number of problems correctly answered are generated as objective measures related to "academic productivity." A positive score indicates improvement.
| Number attempted | Dex-Methylphenidate Hydrochloride (Focalin XR) 20 mg | Dex-Methylphenidate Hydrochloride (Focalin XR) 30 mg | Placebo |
|---|---|---|---|
| Change From Pre-dose in the Permanent Product Measure of Performance of Measurement (PERMP) Math Test-Attempted Score at 10, 11, and 12 Hours (Averaged) Post-dose | 18.76 ± 3.065 | 28.03 ± 3.078 | -0.23 ± 3.073 |
Permanent Product Measure of Performance of Measurement (PERMP) is an age-adjusted, paper-and-pencil math test consisting of 5 pages of 80 math problems each presented in ascending order of difficulty (requiring addition, subtraction, multiplication, and division computations, respectively) during a 10-minute time period. At the end of the 10-minute math test, papers are collected and scored; the number of problems attempted and the number of problems correctly answered are generated as objective measures related to "academic productivity." A positive score indicates improvement.
| Number correct | Dex-Methylphenidate Hydrochloride (Focalin XR) 20 mg | Dex-Methylphenidate Hydrochloride (Focalin XR) 30 mg | Placebo |
|---|---|---|---|
| Change From Pre-dose in the Permanent Product Measure of Performance of Measurement (PERMP) Math Test-Correctly Answered Score at 10, 11, and 12 Hours (Averaged) Post-dose | 18.45 ± 2.461 | 28.02 ± 2.480 | -4.30 ± 2.474 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dex-Methylphenidate Hydrochloride (Focalin XR) 30 mg | — | 0/165 (0%) | 10/165 (6.1%) |
| Dex-Methylphenidate Hydrochloride (Focalin XR) 20 mg | — | 1/165 (0.6%) | 8/165 (4.8%) |
| Placebo | — | 0/165 (0%) | 0/165 (0%) |
| Event | Dex-Methylphenidate Hydrochloride (Focalin XR) 30 mg | Dex-Methylphenidate Hydrochloride (Focalin XR) 20 mg | Placebo |
|---|---|---|---|
| Peritonsillar abscessInfections and infestations | 0/165 | 1/165 | 0/165 |
| Event | Dex-Methylphenidate Hydrochloride (Focalin XR) 30 mg | Dex-Methylphenidate Hydrochloride (Focalin XR) 20 mg | Placebo |
|---|---|---|---|
| Decreased appetiteMetabolism and nutrition disorders | 10/165 | 8/165 | 0/165 |
| Age Continuous(Years) | Focalin XR 20 mg First, Then Focalin XR 30 mg, Then Placebo | Focalin XR 30 mg First, Then Placebo, Then Focalin XR 20 mg | Focalin XR 30 mg First, Then Focalin XR 20 mg, Then Placebo | Placebo First, Then Focalin XR 20 mg, Then Focalin XR 30 mg | Focalin XR 20 mg First, Then Placebo, Then Focalin XR 30 mg | Placebo First, Then Focalin XR 30 mg, Then Focalin XR 20 mg | Total |
|---|---|---|---|---|---|---|---|
| Mean | 9.3 ± 1.7 | 9.4 ± 1.7 | 10.0 ± 1.8 | 9.4 ± 2.0 | 9.5 ± 1.8 | 9.6 ± 2.0 | 9.6 ± 1.8 |
| Sex: Female, Male(Participants) | Focalin XR 20 mg First, Then Focalin XR 30 mg, Then Placebo | Focalin XR 30 mg First, Then Placebo, Then Focalin XR 20 mg | Focalin XR 30 mg First, Then Focalin XR 20 mg, Then Placebo | Placebo First, Then Focalin XR 20 mg, Then Focalin XR 30 mg | Focalin XR 20 mg First, Then Placebo, Then Focalin XR 30 mg | Placebo First, Then Focalin XR 30 mg, Then Focalin XR 20 mg | Total |
|---|---|---|---|---|---|---|---|
| Female | 9 | 16 | 10 | 10 | 12 | 14 | 71 |
| Male | 17 | 12 | 19 | 17 | 16 | 13 | 94 |
| Region of Enrollment(participants) | Focalin XR 20 mg First, Then Focalin XR 30 mg, Then Placebo | Focalin XR 30 mg First, Then Placebo, Then Focalin XR 20 mg | Focalin XR 30 mg First, Then Focalin XR 20 mg, Then Placebo | Placebo First, Then Focalin XR 20 mg, Then Focalin XR 30 mg | Focalin XR 20 mg First, Then Placebo, Then Focalin XR 30 mg | Placebo First, Then Focalin XR 30 mg, Then Focalin XR 20 mg | Total |
|---|---|---|---|---|---|---|---|
| United States | 26 | 28 | 29 | 27 | 28 | 27 | 165 |
The record gives a start of Oct 2008, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2011, 2 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexmethylphenidate
Attention Deficit Disorder with Hyperactivity →